However, neither tumoral IDO1 expression of selected patients nor Kyn levels as a biomarker for IDO1 were evaluated.[7] Therefore, inhibition of IDO1 by means of new inhibitor chemotypes remains a promising opportunity to enhance immune cell‐mediated elimination of cancer cells. Here, IDO1 is linked to cancer.